8-KRegulation FD

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Sep 10, 2026)

Filed September 10, 2026For Securities:ELV

Summary

Elevance Health, Inc. (ELV) has filed an 8-K report on September 10, 2026, to reaffirm its financial guidance for the full year 2026. The company expects shareholders' earnings to be at least $20.10 per diluted share, which includes approximately $6.90 per diluted share related to net unfavorable items. Excluding these specific items, Elevance Health maintains its adjusted shareholders' earnings expectation of at least $27.00 per diluted share. This guidance does not account for any additional adjustment items beyond those already reported in the second quarter of 2026. Furthermore, the company is reaffirming its full-year 2026 guidance for the benefit expense ratio, projecting it to be 90.2%, with a permissible range of plus or minus 50 basis points. This reaffirmation indicates management's confidence in their ability to manage costs and maintain projected profitability within the specified parameters. Investors should note that the information provided is forward-looking and subject to the risks and uncertainties outlined in the filing.

Key Highlights

  • 1Reaffirms full year 2026 shareholders' earnings guidance of at least $20.10 per diluted share.
  • 2Includes approximately $6.90 per diluted share in net unfavorable items within the earnings guidance.
  • 3Maintains expectation for adjusted shareholders' earnings of at least $27.00 per diluted share for full year 2026.
  • 4Guidance for adjusted earnings excludes additional adjustment items beyond Q2 2026 reported items.
  • 5Reaffirms full year 2026 benefit expense ratio guidance of 90.2% +/- 50 basis points.
  • 6Information provided is for investor and analyst meetings over the coming weeks.
  • 7All statements are forward-looking and subject to significant risks and uncertainties.

Frequently Asked Questions

Elevance Health has reaffirmed its guidance for full year 2026 shareholders' earnings to be at least $20.10 per diluted share. This figure includes approximately $6.90 per diluted share of net unfavorable items. Excluding these specific items, the company continues to expect adjusted shareholders' earnings to be at least $27.00 per diluted share.

The company is reaffirming its full year 2026 benefit expense ratio guidance of 90.2%, with a tolerance of plus or minus 50 basis points.

Company officers will be speaking with investors and analysts over the next several weeks. During these meetings, they will reaffirm the company's financial guidance for the full year 2026, including earnings and benefit expense ratios. It is important to note that this information is considered forward-looking and is subject to the risks and uncertainties detailed in the filing.

The reported shareholders' earnings guidance of at least $20.10 per diluted share includes approximately $6.90 per diluted share of net unfavorable items. The adjusted shareholders' earnings guidance of at least $27.00 per diluted share excludes these specific items and does not include any other adjustment items beyond those reported in the company's second quarter 2026 earnings.